Girasole Christopher R, Cookson Michael S, Putzi Mathew J, Chang Sam S, Smith Joseph A, Wells Nancy, Oppenheimer Jonathan R, Shappell Scott B
OUR Lab and Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
J Urol. 2006 Mar;175(3 Pt 1):929-33; discussion 933. doi: 10.1016/S0022-5347(05)00338-1.
We reviewed our results from a urological pathology reference laboratory with respect to the incidence of HGPIN, and atypical and suspicious lesions in the spectrum of ASAP. Subsequent CaP findings on repeat biopsy with relevant clinical implications were assessed.
A review of 42,667 prostate biopsies was performed. We defined atypical and suspicious as variants of ASAP with suspicious being more worrisome for CaP. Findings were correlated with the location of CaP on repeat prostate biopsy.
The rate of subsequent CaP detection was significantly higher for an initial diagnosis of suspicious findings (51% or 54 of 107 cases) than for atypical findings (34% or 39 of 116) or HGPIN (22% or 79 of 358, p < 0.001). CaP was found on the same side of the prostate in 61 of 78 (78%), 30 of 39 (77%) and 41 of 54 patients (76%) with initial HGPIN, atypical and suspicious biopsies, respectively. There was no significant difference among the 3 groups in the likelihood of future CaP at the same site or the same side of the prostate.
Patients with a suspicious biopsy were significantly more likely to have CaP on future biopsy than those with atypical findings or HGPIN, suggesting that there may be divisions with prognostic significance in the larger category of ASAP. To our knowledge the reproducibility of recognizing such divisions remains to be established. Neither atypical nor suspicious lesions were more likely than HGPIN to predict CaP at the same site or side of the prostate as the original diagnosis. Repeat biopsy may be indicated in any patient with HGPIN, or atypical or suspicious lesions and this biopsy should not be limited to the site or side of the original pathological findings.
我们回顾了泌尿外科病理参考实验室关于高级别前列腺上皮内瘤变(HGPIN)以及非典型和可疑病变在非典型小腺泡增生(ASAP)谱系中的发生率。对重复活检时随后发现的前列腺癌(CaP)结果及其相关临床意义进行了评估。
对42667例前列腺活检进行了回顾。我们将非典型和可疑病变定义为ASAP的变异型,其中可疑病变对CaP而言更令人担忧。研究结果与重复前列腺活检时CaP的位置相关联。
对于初始诊断为可疑病变的患者,随后检测到CaP的比率(51%,即107例中的54例)显著高于非典型病变患者(34%,即116例中的39例)或HGPIN患者(22%,即358例中的79例,p<0.001)。在最初诊断为HGPIN、非典型和可疑病变的患者中,分别有78例中的61例(78%)、39例中的30例(77%)和54例中的41例(76%)在前列腺的同一侧发现了CaP。在这三组中,未来在前列腺同一部位或同一侧发生CaP的可能性没有显著差异。
活检结果为可疑的患者在未来活检时发生CaP的可能性显著高于活检结果为非典型病变或HGPIN的患者,这表明在更大范畴的ASAP中可能存在具有预后意义的分类。据我们所知,识别此类分类的可重复性仍有待确定。非典型或可疑病变在预测与初始诊断相同的前列腺部位或同一侧发生CaP方面并不比HGPIN更具可能性。对于任何患有HGPIN、非典型或可疑病变的患者都可能需要进行重复活检,并且这种活检不应局限于原始病理结果的部位或一侧。